MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.130
+0.040
+1.91%
After Hours: 2.075 -0.055 -2.59% 17:02 09/17 EDT
OPEN
2.070
PREV CLOSE
2.090
HIGH
2.130
LOW
2.050
VOLUME
259.83K
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
1.460
MARKET CAP
105.45M
P/E (TTM)
-1.9557
1D
5D
1M
3M
1Y
5Y
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, today announced that Jeffrey Stein, Ph.D., president and chief e...
GlobeNewswire · 09/07 12:00
Cidara Therapeutics to Host Research and Development Day
Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal infections in cancer patients, and the unmet medical need in respi...
GlobeNewswire · 09/02 12:00
Cidara Therapeutics makes key appointments
Cidara Therapeutics (NASDAQ:CDTX) appoints Preetam Shah, Ph.D., MBA, as CFO and chief business officer, and Shane Ward as chief legal officer and corporate secretary. Prior to joining Cidara, Dr. Shah served as the executive VP,
Seekingalpha · 09/01 12:40
2 Biotech Stocks Wall Street Predicts Will Double
StockNews.com · 08/27 16:10
Cidara Therapeutics Inc (CDTX) President & CEO Jeffrey Stein Bought $87,000 of Shares
GuruFocus News · 08/19 12:51
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Top-line data anticipated in late 2021
GlobeNewswire · 08/17 12:00
Bullish: Analysts Just Made A Meaningful Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Forecasts
Shareholders in Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) may be thrilled to learn that the analysts have just...
Simply Wall St. · 08/17 10:17
Cidara Therapeutics Completes Patient Enrollment for Late-Stage Study of Fungal Infections Drug Candidate
MT Newswires · 08/17 08:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDTX. Analyze the recent business situations of Cidara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDTX stock price target is 6.17 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 24.45M
% Owned: 49.39%
Shares Outstanding: 49.51M
TypeInstitutionsShares
Increased
10
1.54M
New
14
1.86M
Decreased
22
3.48M
Sold Out
21
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Burgess
President/Chief Executive Officer/Chief Financial Officer/Director
Jeffrey Stein
Chief Financial Officer
Preetam Shah
Chief Operating Officer
Paul Daruwala
Chief Accounting Officer/Vice President - Finance
Brady Johnson
General Counsel/Secretary
Jessica Oien
Other
Taylor Sandison
Independent Director
Bonnie Bassler
Independent Director
Carin Canale - Theakston
Independent Director
Timothy Franson
Independent Director
David Gollaher
Independent Director
Chrysa Mineo
Independent Director
Theodore Schroeder
No Data
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.